Apollo Medical Holdings Inc ASTH Stock Analysis
- Nasdaq
- Stock
- Market closed · opens Monday 9:30 AM ET
$36.81 down $1.22, 3.21% at close Oct 16
Last close · Previous close $38.03
- Market cap
- At the Oct 16 close
- P/E ratio
- 44.35On last 12 months’ EPS
- Diluted EPS
- $0.83Last 12 months
- Dividend yield
- NoneLast 12 months
Price chart
$36.81down $1.22, 3.21%Fri, Oct 16 session
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$38.03Oct 15
- Volume239.99KOct 16 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume411.85KLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $18.08 to $51.60; now $36.81
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Oct 16 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
ASTH beat the S&P 500 in 2 of 7 periods.
| Period | ASTH and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | ASTH: down 2.4% S&P 500: up 1.5% | ASTH trailed the S&P 500 by 3.9 percentage points Trailed |
| 3M | ASTH: down 18.4% S&P 500: up 1.9% | ASTH trailed the S&P 500 by 20.3 percentage points Trailed |
| YTD | ASTH: up 48.4% S&P 500: up 12.8% | ASTH beat the S&P 500 by 35.6 percentage points Beat |
| 1Y | ASTH: up 15.8% S&P 500: up 16.8% | ASTH trailed the S&P 500 by 1.0 percentage points Trailed |
| Long term | ||
| 3Y | ASTH: up 17.5% S&P 500: up 81.5% +5.5% vs +22.0% a year | ASTH trailed the S&P 500 by 64.0 percentage points Trailed |
| 5Y | ASTH: down 48.5% S&P 500: up 83.1% −12.4% vs +12.9% a year | ASTH trailed the S&P 500 by 131.6 percentage points Trailed |
| 10Y | ASTH: up 873.8% S&P 500: up 319.6% +25.6% vs +15.4% a year | ASTH beat the S&P 500 by 554.2 percentage points Beat |
$10,000 invested in ASTH 10 years ago (Oct 14, 2016) would be worth about $97,381 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $41,964.
ASTH beat the S&P 500 in 3 of 7 periods.
| Period | ASTH and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | ASTH: down 2.4% S&P 500: up 1.2% | ASTH trailed the S&P 500 by 3.6 percentage points Trailed |
| 3M | ASTH: down 18.4% S&P 500: up 1.7% | ASTH trailed the S&P 500 by 20.1 percentage points Trailed |
| YTD | ASTH: up 48.4% S&P 500: up 11.9% | ASTH beat the S&P 500 by 36.5 percentage points Beat |
| 1Y | ASTH: up 15.8% S&P 500: up 15.5% | ASTH beat the S&P 500 by 0.3 percentage points Beat |
| Long term | ||
| 3Y | ASTH: up 17.5% S&P 500: up 75.0% +5.5% vs +20.5% a year | ASTH trailed the S&P 500 by 57.5 percentage points Trailed |
| 5Y | ASTH: down 48.5% S&P 500: up 71.2% −12.4% vs +11.4% a year | ASTH trailed the S&P 500 by 119.7 percentage points Trailed |
| 10Y | ASTH: up 873.8% S&P 500: up 258.1% +25.6% vs +13.6% a year | ASTH beat the S&P 500 by 615.7 percentage points Beat |
$10,000 invested in ASTH 10 years ago (Oct 14, 2016) would be worth about $97,381 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $35,813.
All-time high
$119.45
Closing high on . Now 69.2% below that record.
Split-adjusted daily closes since Feb 23, 2011.
Stock splits
ASTH hasn’t split since its price history begins in 2011.
Valuation
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q2 FY26, the quarter ended Jun 30, 2026. “Last 12 months” means the four quarters from Jul 1, 2025 to Jun 30, 2026, and balance-sheet figures are as of Jun 30, 2026.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $3.84Bup 58.9%
- Net income
- $40.55Mup 60.5%
- Diluted EPS
- $0.83up 59.6%
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q3 FY24 (Sep 30, 2024) | $478.71M | $16.09M | $0.33 |
| Q4 FY24 (Dec 31, 2024) | $665.21M | −$6.95M | −$0.14 |
| Q1 FY25 (Mar 31, 2025) | $620.39M | $6.69M | $0.14 |
| Q2 FY25 (Jun 30, 2025) | $654.81M | $9.42M | $0.19 |
| Q3 FY25 (Sep 30, 2025) | $956.05M | $373.00K | $0.01 |
| Q4 FY25 (Dec 31, 2025) | $950.53M | $6.00M | $0.13 |
| Q1 FY26 (Mar 31, 2026) | $965.10M | $14.44M | $0.29 |
| Q2 FY26 (Jun 30, 2026) | $972.52M | $19.74M | $0.40 |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY21 (Dec 31, 2021) | $773.92M | $68.92M | $1.52 |
| FY22 (Dec 31, 2022) | $1.14B | $45.17M | $0.99 |
| FY23 (Dec 31, 2023) | $1.39B | $60.72M | $1.29 |
| FY24 (Dec 31, 2024) | $2.03B | $43.15M | $0.90 |
| FY25 (Dec 31, 2025) | $3.18B | $22.49M | $0.46 |
Margins
- Gross 10.5%
- Operating 2.6%
- Net 1.1%
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- $94.38MLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow$107.87MLast 12 months
- Capital spending$13.49MLast 12 months
- 2.5%Last 12 months
Free cash flow as a share of revenue, both over the last 12 months.
Shareholder returns
- $18.24MLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paid$1.85MLast 12 months
- Total returned$20.09MLast 12 months
21% of free cash flow
Balance sheet
- $481.19MAs of Jun 30, 2026
Cash plus short- and long-term marketable securities on the Jun 30, 2026 balance sheet.
- Total debt$979.41MAs of Jun 30, 2026
- Net debt$498.22MAs of Jun 30, 2026
- 1.23As of Jun 30, 2026
Current assets divided by current liabilities on the Jun 30, 2026 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio - 1.18As of Jun 30, 2026
Total debt divided by shareholders’ equity on the Jun 30, 2026 balance sheet: a measure of financial leverage.
D/E = Total debt ÷ Shareholders’ equityDebt-to-equity ratio
Financial strength
- 6 of 9Last 12 months
vs the 12 beforeA 0–9 checklist from accounting professor Joseph Piotroski. Each test compares the last 12 months with the 12 months before and scores a point if it passes. 8–9 is strong; 0–2 is weak.
- ✓Net income was positive: passed
- ✓Operating cash flow was positive: passed
- ✓Return on assets improved: passed
- ✓Operating cash flow exceeded net income: passed
- ✗Long-term debt fell relative to assets: not passed
- ✗Current ratio improved: not passed
- ✓Share count didn’t rise: passed
- ✗Gross margin improved: not passed
- ✓Asset turnover (revenue ÷ assets) improved: passed
- 5.1%Last 12 months
Over the last 12 months, Apollo Medical Holdings’s net income was 5.1% of its shareholders’ equity (averaged over the last four quarter-ends). It describes the past year, not an expected return.
ROE = Net income (last 12 months) ÷ Average equityReturn on equity - 1.8%Last 12 months
Over the last 12 months, Apollo Medical Holdings’s net income was 1.8% of its total assets (averaged over the last four quarter-ends): what the business earned on everything it owns.
ROA = Net income (last 12 months) ÷ Average total assets
About Apollo Medical Holdings Inc
ApolloMed is a leading provider-centric, technology-powered healthcare company enabling providers to deliver accessible, high-quality, and high-value care to all. Leveraging its proprietary end-to-end technology solutions, ApolloMed operates an integrated healthcare delivery platform that enables providers to successfully participate in value-based care arrangements, thus empowering them to deliver high quality care to patients in a cost-effective manner. Headquartered in Alhambra, California, ApolloMed's subsidiaries and affiliates include management services organizations (MSOs), affiliated independent practice associations (IPAs), and entities participating in the Centers for Medicare & Medicaid Services Innovation Center (CMMI) innovation models.
- Sector
- Healthcare
- Industry
- Medical Care Facilities
- Headquarters
- California, USA
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
ASTH news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
ASTH stock FAQ
What is ASTH stock’s price today?
Apollo Medical Holdings (ASTH) traded at $36.81 at the close on , down $1.22 (3.21%) from the previous close of $38.03. Over the past 52 weeks it has traded between $18.08 and $51.60.
If you invested $1,000 in ASTH 10 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in ASTH on would be worth about $9,738 at the close on , a total return of +873.8%. The same $1,000 would be worth $515 if invested five years ago and $1,158 if invested one year ago. Past performance doesn’t predict future returns.
What is ASTH’s P/E ratio?
ASTH trades at 44.3 times its diluted earnings over the four quarters to ($0.83 per share), at the close. (How the P/E ratio works.)
How much revenue does Apollo Medical Holdings make?
Apollo Medical Holdings reported $3.8 billion of revenue over the four quarters to , up 58.9% from the twelve months before. In its latest quarter (Q2 FY26, ended ) revenue was $972.5 million, up 48.5% from a year earlier.
Is Apollo Medical Holdings profitable?
Yes. Apollo Medical Holdings earned $40.5 million of net income over the four quarters to , a net margin of 1.1%, and its operating margin was 2.6% (what margins tell you).
What are ASTH’s earnings per share?
ASTH’s diluted earnings per share were $0.83 over the four quarters to , compared with $0.52 in the twelve months before. The latest quarter (Q2 FY26) brought $0.40 per share, against $0.19 a year earlier (how EPS works).
Does ASTH pay a dividend?
Apollo Medical Holdings hasn’t paid a dividend in the last twelve months.
What is ASTH’s 52-week high and low?
Over the past 52 weeks ASTH has traded as low as $18.08 and as high as $51.60. At $36.81 at the close on , it is 28.7% below that high and 103.6% above the low.
What is ASTH’s all-time high?
ASTH’s highest closing price was $119.45 on , adjusted for stock splits. At $36.81 at the close on , it is 69.2% below that record.
Has ASTH stock ever split?
No. ASTH hasn’t split since its price history begins in 2011.
How has ASTH stock performed?
Including dividends and measured to the close on , ASTH has returned +48.4% so far this year and +15.8% over the past year, and −48.5% over five years (−12.4% a year). Over the same periods the S&P 500, measured by SPY, returned +12.8%, +16.8% and +83.1%. Past performance doesn’t predict future returns.
What sector and industry is Apollo Medical Holdings in?
Apollo Medical Holdings is in the Healthcare sector and the Medical Care Facilities industry, and is headquartered in California, USA.
What exchange does ASTH trade on?
Apollo Medical Holdings trades on the Nasdaq under the ticker symbol ASTH. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.